Urologic Oncology-seminars And Original Investigations杂志是一本国际优秀期刊，是一本未开放获取期刊。该杂志近三年影响因子分别为：2026年2.8、2025年2.3、2024年2.4。该杂志近三年CiteScore评价值分别为：2025年4.6、2024年5、2023年4.8。该刊专门致力于推进肿瘤学领域的研究，涵盖了肿瘤学领域的各个方面，汇集所有专家，促进肿瘤学领域的更好协作和信息共享。该期刊为肿瘤学领域的科研人员提供了一个高影响力的论坛，使该领域的科研人员、从业人员和学生能够接触到尖端的经验性调查分析、学术对话以及行业科研成果的最新发展。通过收录高质量的原创论文和评论论文，促进肿瘤学领域的应用与发展。该期刊还将该领域的创新与应用，以提高研究的质量和实用性。近年来在该刊上发文的国家和地区主要有：Uruguay（发文量1）、USA（发文量483）、UNITED ARAB EMIRATES（发文量1）、Turkey（发文量9）、Taiwan（发文量11）、Switzerland（发文量43）。
Urologic Oncology-seminars And Original Investigations是一本由Elsevier Inc.出版社发行的知名肿瘤学期刊。该杂志社联系方式ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710。审稿过程是确保期刊质量的关键环节。Urologic Oncology-seminars And Original Investigations杂志的审稿速度平均需要偏慢,4-8周。这一时间周期既体现了编辑部对稿件质量的严格把关，也反映了审稿专家对学术研究的尊重和支持。在这个过程中，作者们可以充分利用这段时间对自己的研究成果进行完善和优化，以提高论文的质量和影响力。如果您对该期刊感兴趣，并希望了解更多关于投稿流程、投稿要求和技巧的信息，您可以咨询本站的客服老师，我们将帮助您了解期刊的投稿要求、审稿流程以及可能遇到的问题，并根据您的具体情况提供相应的建议和解决方案。
Urologic Oncology-seminars And Original Investigations杂志近期中国学者发表的论文主要有：
-
1、Combined and individual effects of neoadjuvant chemotherapy and lymph node dissection on survival in non-muscle-invasive bladder cancer undergoing radical cystectom
Author: Sheng, Yiyu; Fan, Longlong; Zhu, Sikun; Wang, Yiran; Zhang, Shiqiang; Xiong, Haiyun
-
2、Comparison of prostate cancer detection rates between micro-ultrasound-guided and multiparametric magnetic resonance imaging-guided prostate biopsy: A systematic review and meta-analysis of prospective studie
Author: Lu, Yiqiao; Zhao, Dan; Han, Yong; Guo, Yiting; Dong, Yinan
-
3、Perioperative and oncologic outcomes of extirpative surgery for upper tract urothelial cancer in octogenarian
Author: Li, Taibo; Bronimann, Stephan; Eraky, Ahmed; Lopez, Carlos Rivera; Cheaib, Joseph; Bignante, Gabriele; Wu, Zhenjie; Wang, Linhui; Simone, Giuseppe; Tuderti, Gabriele; Ferro, Matteo; Decobelli, Ottavio; Sundaram, Chandru P.; Sidhom, Daniel; Yoshida, Takashi; Perdona, Sisto; Tufano, Antonio; Ghodoussipour, Saum; Fu, Melinda; Shah, Ankeet; Ghoreifi, Alireza; Porter, James; Correa, Andres F.; Rais-Bahrami, Soroush; Moon, Sol C.; Derweesh, Ithaar H.; Puri, Dhruv; Meagher, Margaret F.; Minervini, Andrea; Lambertini, Luca; Porpiglia, Francesco; Amparore, Daniele; Checcucci, Enrico; Gonzalgo, Mark L.; Faliknativ, Omri; Margulis, Vitaly; Taylor, Jacob; Cusmano, Nicholas B.; Abdollah, Firas; Veccia, Alessandro; Ditonno, Francesco; Antonelli, Alessandro; Moghaddam, Farshad S.; Djaladat, Hooman; Autorino, Riccardo; Mehrazin, Reza; Singla, Nirmish
-
4、LncRNA NPSR1-AS1 affects the malignant biological behavior of bladder cancer through miR-199a-3p and the clinical value of urine-derived lncRNA NPSR1-AS
Author: He, Weijing; Wen, Yong; Qin, Huiling
-
5、Pharmacologic synergy versus independent action in androgen receptor-axis-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysi
Author: Chen, Wei; Yoshida, Soichiro; Yajima, Shugo; Sato, Hiroyuki; Hirakawa, Akihiro; Tanabe, Kenji; Fukushima, Hiroshi; Yasuda, Yosuke; Tanaka, Hajime; Masuda, Hitoshi; Fujii, Yasuhisa
-
6、Efficacy and safety of tislelizumab plus intravesical chemotherapy in recurrent high-risk non-muscle-invasive bladder cancer: A retrospective single-center real-world stud
Author: Chen, Qing; Wu, Rongpan; Zhang, Chen; Xie, Jiaxin; Wang, Yi; Yu, Xufeng; He, Wei; Wang, Maoyu; Zhao, Junjie; Zhang, Zhensheng; Zeng, Shuxiong; Xu, Chuanliang
